PubRank

S Plotkin

Author PubWeight™ 58.04‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature 1979 6.76
2 Growth characteristics of cytomegalovirus in human fibroblasts with demonstration of protein synthesis early in viral replication. J Virol 1973 3.48
3 Immunisation with canarypox virus expressing rabies glycoprotein. Lancet 1992 2.09
4 Predictors of morbidity and mortality in neonates with herpes simplex virus infections. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. N Engl J Med 1991 1.97
5 Summary of a workshop on new and useful methods in viral diagnosis. J Infect Dis 1978 1.87
6 Rapid detection of human cytomegalovirus in the urine of humans. J Infect Dis 1985 1.85
7 A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. Infectious Diseases Collaborative Antiviral Study Group. N Engl J Med 1991 1.73
8 Outbreak of poliomyelitis-like paralysis associated with enterovirus 71. Pediatr Infect Dis J 1989 1.67
9 Ultrastructural study on the sequence of human cytomegalovirus infection in human diploid cells. Arch Gesamte Virusforsch 1973 1.47
10 Inactivated poliovirus vaccine: past and present experience. Vaccine 1996 1.22
11 The prime-boost concept applied to HIV preventive vaccines. AIDS 1997 1.20
12 Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in healthy individuals: reevaluation of prevalence of IE1-specific CTLs. J Infect Dis 2000 1.16
13 Summary of a workshop on new and useful methods in rapid viral diagnosis. J Infect Dis 1984 1.13
14 A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects. J Infect Dis 2001 1.12
15 Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le Sida. AIDS Res Hum Retroviruses 1999 1.05
16 Characterization of multiple molecular interactions between human cytomegalovirus (HCMV) and human immunodeficiency virus type 1 (HIV-1). Virology 1990 1.05
17 Prevention of diabetes in rats by bone marrow transplantation. Ann Surg 1981 1.05
18 A rapid accurate procedure for the determination of serotonin in whole human blood. Biochem Med 1970 1.00
19 Canarypox virus-based vaccines: prime-boost strategies to induce cell-mediated and humoral immunity against HIV. AIDS Res Hum Retroviruses 1998 0.99
20 Efficacy and safety of a Haemophilus influenzae type b capsular polysaccharide-tetanus protein conjugate vaccine. J Pediatr 1992 0.99
21 Use of predictive markers of HIV disease progression in vaccine trials. Vaccine 2009 0.99
22 Life-threatening complications of varicella. Am J Dis Child 1981 0.98
23 From the National Institute of Allergy and Infectious Diseases. Summary of a workshop on new and useful techniques in rapid viral diagnosis. J Infect Dis 1980 0.96
24 Development of a cytomegalovirus vaccine: lessons from recent clinical trials. Expert Opin Biol Ther 2001 0.96
25 Preparing for elimination of congenital Rubella syndrome (CRS): summary of a workshop on CRS elimination in the United States. Clin Infect Dis 2000 0.94
26 Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system. Vaccine 1996 0.93
27 Progress in vaccine development for prevention of human cytomegalovirus infection. Curr Top Microbiol Immunol 1990 0.93
28 Increased blood serotonin and platelets in early infantile autism. Arch Gen Psychiatry 1970 0.92
29 Retracted Generation of deletion mutants of simian immunodeficiency virus incapable of proviral integration. J Virol 1992 0.91
30 Human cytomegalovirus induces stage-specific embryonic antigen 1 in differentiating human teratocarcinoma cells and fibroblasts. J Exp Med 1989 0.90
31 Lessons learned from a review of the development of selected vaccines. National Vaccine Advisory Committee. Pediatrics 1999 0.89
32 High expression of human cytomegalovirus (HCMV)-gB protein in cells infected with a vaccinia-gB recombinant: the importance of the gB protein in HCMV immunity. Vaccine 1991 0.83
33 Synthesis of virus and macromolecules by rubella-infected cells. Nature 1966 0.83
34 Maturational changes in blood serotonin levels and platelet counts. Biochem Med 1971 0.81
35 Antiplatelet antibodies during the course of HIV-preventive vaccine trial. AIDS 1996 0.81
36 Fifteen years of experience with Vero-produced enhanced potency inactivated poliovirus vaccine. Pediatr Infect Dis J 1997 0.81
37 Effects of L-dopa in autism. J Autism Child Schizophr 1972 0.80
38 Haemagglutinin of rubella virus. Nature 1967 0.80
39 Evaluation of Abbott CMV-M enzyme immunoassay for detection of cytomegalovirus immunoglobulin M antibody. J Clin Microbiol 1988 0.80
40 Neonatal mastitis due to Escherichia coli. J Pediatr 1970 0.80
41 Isolated gA/gB glycoprotein complex of human cytomegalovirus envelope induces humoral and cellular immune-responses in human volunteers. Vaccine 1990 0.79
42 Serologic survey of antibodies to cytomegalovirus in women and infants in Lima, Peru. J Infect Dis 1983 0.79
43 Distribution of bacteria in the operating room environment and its relation to ventricular shunt infections: a prospective study. Childs Nerv Syst 1991 0.78
44 Clinical development of a new inactivated hepatitis A vaccine. Infection 1997 0.77
45 Booster vaccination at 1 year with a rabies vaccine associated with DTP-IPV in infants living in a rabies endemic country. J Trop Pediatr 1999 0.77
46 History of the acceptance of human diploid cell strains as substrates for human virus vaccine manufacture. Dev Biol Stand 1987 0.76
47 Management of heel pain syndrome with acetic acid iontophoresis. J Am Podiatr Med Assoc 1999 0.75
48 The anti-inflammatory action of locally injected ketorolac. J Am Podiatr Med Assoc 1998 0.75
49 Bridging the gap-a reply. J Theor Biol 2000 0.75
50 Formation of covalently closed cyclic dimers and catenanes of Escherichia coli phage lambda in the absence of known recombination systems. Virology 1976 0.75
51 [Vaccination perspectives]. Sante 1994 0.75
52 Safety and immunogenicity of acellular pertussis vaccine combined with diphtheria and tetanus toxoids in 17- to 24-month-old children. Pediatr Infect Dis J 1992 0.75
53 DNA synthesis in chromatin preparations from human fibroblasts infected by cytomegalovirus. Arch Virol 1980 0.75
54 First reported successful management of Serratia marcescens bacteremia after open heart surgery in a child. J Pediatr Surg 1975 0.75
55 Generation of deletion mutants of simian immunodeficiency virus incapable of proviral integration. J Virol 1993 0.75
56 Multiple bioassays to assess the toxicity of a sanitary landfill leachate. Arch Environ Contam Toxicol 1984 0.75
57 Clinical comparison of preinjection anesthetics. J Am Podiatr Med Assoc 1998 0.75
58 Prevention of cytomegalovirus disease. Report of a conference. Pediatr Infect Dis 1984 0.75
59 [Pediatric vaccines tomorrow]. Arch Pediatr 1996 0.75
60 In utero fetal lower extremity examination by diagnostic ultrasound. J Am Podiatr Med Assoc 1988 0.75
61 Case presentation of calcaneonavicular coalition in monozygotic twins. J Am Podiatr Med Assoc 1996 0.75
62 Viral vaccine meeting held in Barcelona, October 25-28, 2003. Vaccine 2004 0.75
63 Providing MMR vaccine to children. Minn Med 1991 0.75
64 Effect of neonatal corticoid treatment on tryptophan and serotonin metabolism. Endocrinol Exp 1978 0.75
65 Postsynaptic adrenergic-cyclic AMP control of the serotonin content of cultured rat pineal glands. J Neurochem 1973 0.75
66 St. Thomas Immunization Initiative. A student-run community action project. J La State Med Soc 1997 0.75